These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2519428)

  • 1. [In vitro activity of ampicillin and ampicillin-sulbactam on diverse bacteria].
    Trucco O; Prado V; Mollinedo E; Cordoves A
    Rev Med Chil; 1989 Jul; 117(7):747-54. PubMed ID: 2519428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
    Itokazu GS; Danziger LH
    Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria].
    González C; García A; Urrea R; del Solar E; Bello H; Zemelman R
    Rev Med Chil; 1990 May; 118(5):548-54. PubMed ID: 2293275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide clinical experience with sultamicillin.
    Pitts NE; Gilbert GS; Knirsch AK; Noguchi Y
    APMIS Suppl; 1989; 5():23-34. PubMed ID: 2660868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactamase production and the role of ampicillin/sulbactam.
    Alpuche-Aranda CM
    Pediatr Infect Dis J; 1998 Mar; 17(3 Suppl):S8-11; discussion S20-1. PubMed ID: 9519908
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sultamicillin versus trimethoprim/sulfamethoxazole in the treatment of urinary tract infections.
    Naber KG; Wittenberger R
    APMIS Suppl; 1989; 5():57-62. PubMed ID: 2660873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of sulbactam/ampicillin against ampicillin-resistant, beta-lactamase-producing bacteria isolated in Italian hospitals.
    Varaldo PE; Ripa S; Nicoletti G; Covelli I; Satta G; Carlone N; Fontana R
    Chemotherapy; 1990; 36(2):141-6. PubMed ID: 2178890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of beta-lactamases by sulbactam and enhanced clinical activity due to target-site binding of the combination of sulbactam and ampicillin.
    Yokota T
    APMIS Suppl; 1989; 5():9-16. PubMed ID: 2786726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
    Wang FD; Lin ML; Lee WS; Liu CY
    Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.